Aciex Enters Into Agreement With Portola to Develop Dual Syk/JAK Inhibitors
Aciex Therapeutics, Inc., announced that it has entered
into a collaborative research agreement with Portola
Pharmaceuticals, Inc., that provides Aciex with exclusive
rights to develop Portola’s small-molecule dual Spleen
tyrosine kinase (Syk)/Janus kinase (JAK) inhibitors for
ophthalmic indications. The two companie...